The RETNLB antibody targets Resistin-like molecule beta (RETNLB), also known as FIZZ2 or RELMβ, a cysteine-rich secretory protein belonging to the resistin family. RETNLB is primarily expressed in intestinal goblet cells and epithelial tissues, playing roles in immune regulation, inflammation, and tissue remodeling. It is implicated in type 2 immune responses, often upregulated during parasitic infections, allergic reactions, and inflammatory bowel diseases (e.g., colitis). RETNLB interacts with extracellular matrix components and immune cells, modulating pathways such as IL-13 signaling, which influences mucus production and barrier function.
Antibodies against RETNLB are essential tools for studying its expression, localization, and function in disease models. They enable detection via techniques like immunohistochemistry, Western blotting, and ELISA, aiding research on RETNLB's contribution to pathologies like colorectal cancer, asthma, and metabolic disorders. Recent studies explore its dual role in promoting inflammation and tissue repair, highlighting context-dependent effects. Commercial RETNLB antibodies are typically raised in rabbits or mice, validated for specificity in human and murine tissues. Ongoing research aims to clarify RETNLB's therapeutic potential, either as a biomarker or a target for modulating immune-mediated diseases.